Prognostic factors for refractory pheochromocytoma and paraganglioma after 131I-metaiodobenzylguanidine therapy
ConclusionsResponse to repeated131I-mIBG treatment can be a strong predictor of prognosis after initial131I-mIBG therapy for refractory PPGL. Repeated131I-mIBG therapy may be a good option for controlling refractory PPGL.
Source: Annals of Nuclear Medicine - Category: Nuclear Medicine Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Constipation | Diabetes | Diabetes Mellitus | Endocrinology | External Beam Therapy | Hypertension | Nuclear Medicine | Pain | Paraganglioma | Pheochromocytoma | Study